Imunon's EVP and CMO Nicholas Borys to depart Feb 28, 2023

Imunon, Inc.

Nicholas Borys, EVP and Chief Medical Officer, will separate effective February 28, 2023.
Borys will receive salary continuation and COBRA premiums for up to 12 months; benefits cease or reduce if new employment is found.
No replacement for the CMO role has been announced at this time.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nicholas Borys

Executive Vice President and Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2023-02-28
Filed: February 10, 2023, 6:59 PM ET

On February 10, 2023, Imunon, Inc., a Delaware corporation (“Imunon”), announced that Nicholas Borys, its Executive Vice President and Chief Medical Officer, would separate from Imunon effective as of February 28, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicholas Borys departed as Executive Vice President and Chief Medical Officer at Imunon, Inc..

Action: separated
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On February 10, 2023, Imunon, Inc., a Delaware corporation (“Imunon”), announced that Nicholas Borys, its Executive Vice President and Chief Medical Officer, would separate from Imunon effective as of February 28, 2023.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-004311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.